Sugi Predict

Sugi Predict / Compounds / SCHEMBL850387

SCHEMBL850387

SCHEMBL850387

CN(C)C(=O)c1ccc(Br)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ NCEH1 Q6PIU2 1/20 0.42
▸ PDK2 Q15119 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ ANPEP P15144 1/20 0.39
▸ MAPK14 Q16539 3/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144208 0.85 ERN1 (0.48) ERN1HPGDSMN1; SMN2ALDH1A1NCEH1
SCHEMBL589423 0.83 MLYCD (0.48) HPGDALDH1A1NCEH1HDAC1HDAC6
SCHEMBL2653855 0.82 CES2 (0.59) ERN1HPGDSMN1; SMN2ALDH1A1PDK2
SCHEMBL27007648 0.81 KIF11 (0.41) ERN1HPGDHDAC1HDAC6CES2
SCHEMBL10266907 0.81 HPGD (0.64) HPGDSMN1; SMN2ALDH1A1PDK2KMT2A
SCHEMBL27002437 0.81 NPSR1 (0.51) HPGDALDH1A1HDAC1HDAC6CES2
SCHEMBL18348174 0.80 PDK2 (0.47) HPGDPDK2HDAC1HDAC6HTT
SCHEMBL2727648 0.80 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1HTTKMT2AMAOB
SCHEMBL16905393 0.79 HDAC1 (0.58) ERN1HPGDSMN1; SMN2ALDH1A1PDK2
SCHEMBL355413 0.79 ESR1 (0.60) ERN1HPGDSMN1; SMN2ALDH1A1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 — — US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
WO-2025064853-A1 RIPK3 INHIBITORS AND METHODS OF USE Momentum Therapeutics, Inc. (US) 2025-03-27 — — WO disclosed
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2025-03-20 — — US disclosed
EP-4335512-A2 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HiberCell, Inc. (US) 2024-03-13 — — EP disclosed
EP-3728217-B1 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2023-11-15 — — EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 — — EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 — — WO disclosed
US-20090099160-A1 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors ASTRAZENECA AB (SE) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE RIPK3, RIPK1, RIPK2 ERN1 186/4885HPGD 3528/4885SMN1; SMN2 1468/4885
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 ERN1 2290/4885HPGD 2068/4885SMN1; SMN2 1005/4885
US-20090099160-A1 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors CCNI, CDK4, CDK3 ERN1 1710/4885HPGD 1514/4885SMN1; SMN2 1922/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ERN1 3694/4885HPGD 1549/4885SMN1; SMN2 3259/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B ERN1 3600/4885HPGD 1739/4885SMN1; SMN2 4449/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 ERN1 1312/4885HPGD 3666/4885SMN1; SMN2 4101/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B ERN1 3368/4885HPGD 1586/4885SMN1; SMN2 3341/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 ERN1 1878/4885HPGD 1725/4885SMN1; SMN2 2651/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ERN1 3694/4885HPGD 1549/4885SMN1; SMN2 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.